Soluble mesothelin neutralizes mesothelin antibody-based therapies.Katherine E. Smith, Aaron S. Mansfield, Jacob J. Orme et al.|Journal of Clinical Oncology|2024Cited by 2
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with <sup>177</sup>Lutetium.Yael Kusne, Mrinal M. Patnaik, Osama Mosalem et al.|Journal of Clinical Oncology|2024Cited by 2
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelinKatherine E. Smith, Aaron S. Mansfield, Jennifer Ayers-Ringler et al.|Scientific Reports|2025Cited by 2
2403P LuRa: Efficacy and Tolerability of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate CancerJonathan Zarka, Donald S. Childs, M. Muniz et al.|Annals of Oncology|2025Cited by 1
LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerJabra Zarka, Daniel S. Childs, Ronit Juthani et al.|Clinical Genitourinary Cancer|2026Cited by 0